Application of microneedle arrays for enhancement of transdermal permeation of Insulin: in vitro experiments, scaling analyses and numerical simulations

This item was submitted to Loughborough University's Institutional Repository by the/an author.

Citation: LEELADURGA, V. ...et al., 2016. Application of microneedle arrays for enhancement of transdermal permeation of Insulin: in vitro experiments, scaling analyses and numerical simulations. AAPS PharmSciTech, 17 (4), pp. 915-922.

Additional Information:

- The final publication is available at Springer via http://dx.doi.org/10.1208/s12249-015-0416-8

Metadata Record: https://dspace.lboro.ac.uk/2134/19315

Version: Accepted for publication

Publisher: © American Association of Pharmaceutical Scientists. Published by Springer

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Please cite the published version.
Application of Microneedle Arrays for Enhancement of Transdermal Permeation of Insulin: In Vitro Experiments, Scaling Analyses and Numerical Simulations

V. Leeladurga¹, U. Chandra Teja¹, S. K. Ashraf Sultana¹, K. Sudeep¹, V. Sai Sri Anusha¹, Tao Han², Buchi N. Nalluri¹,³, and Diganta B. Das²,³

¹ Department of Pharmaceutics, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, 520010, AP, India
² Department of Chemical Engineering, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK
³ To whom correspondence should be addressed. (e-mail: buchinalluri@yahoo.com; D.B.Das@lboro.ac.uk)

ABSTRACT

The aim of this investigation is to study the effect of donor concentration and microneedle (MN) length on permeation of insulin and further evaluating the data using scaling analyses and numerical simulations. Histological evaluation of skin sections was carried to evaluate the skin disruption and depth of penetration by MNs. Scaling analyses was done using dimensionless parameters like concentration of drug (Ct/Cs), thickness (h/L) and surface area of the skin (Sa/L²). Simulation studies were carried out using MATLAB and COMSOL software to simulate the insulin permeation using histological sections of MN treated skin and experimental parameters like passive diffusion coefficient. A 1.6 fold increase in transdermal flux and 1.9 fold decrease in lag time values were observed with 1.5mm MN when compared with passive studies. Good correlation (R²>0.99) was observed between different parameters using scaling analyses. Also, the in vitro and simulated permeations profiles were found to be similar (f²≥50). Insulin permeation significantly increased with increase in donor concentration and MN length (p<0.05). The developed scaling correlations and numerical simulations were found to be accurate and would help researchers to predict the permeation of insulin with new dimensions of MN in optimizing insulin delivery.
Overall, it can be inferred that the application of MNs can significantly enhance insulin permeation and may be an efficient alternative for injectable insulin therapy in humans.

KEY WORDS: Histological studies, Insulin skin permeation, Microneedle arrays, Numerical simulations, Scaling analyses.
INTRODUCTION

Diabetes mellitus is a metabolic disorder, which is characterized by insufficient production of insulin (type I) or failure of the body to utilize the insulin produced (type II). Currently the number of patients suffering from diabetes mellitus is about 285 million adults worldwide, and by the year 2030 the numbers are expected to reach 439 million adults (1). Insulin, a pancreatic peptide hormone, is used in the treatment of insulin dependent diabetes mellitus (IDDM or type-I DM). Insulin is a water soluble, unstable protein with a molecular size more than 5000kDa.

Insulin cannot be administered orally as it is severely degraded in GIT by the process of digestion (2). Drug delivery via the parenteral route, either by subcutaneous or intramuscular injection, is particularly common. Injection by hypodermic needle has been ‘the gold standard’ for insulin delivery for over a century (3). However, administration of insulin by hypodermic needles often causes pain, peripheral hyperinsulinemia, smooth muscle cell proliferation and a diabetic micro- and macro-angiopathy and may transmit pathogens through needle re-use and require medical expertise(4, 5). In addition, the burden of daily injections, patient non-compliance, physiological stress, inconvenience, cost, and the localized deposition of insulin leads to a local hypertrophy and fat deposition in the injection sites. To alleviate these drawbacks, transdermal route for insulin delivery can be used as an alternative non-parenteral route of administration to treat insulin dependent diabetic patients.

Given the very low diffusivity of insulin in stratum corneum owing to its high molecular weight and its hydrophilic nature, an efficient permeation enhancement technique must be employed to enhance the transdermal permeation of insulin.

Literature review revealed that a number of works have been reported on the transdermal delivery of insulin. Some of the works utilized various permeation enhancers alone and along with iontophoresis for insulin permeation enhancement (6, 7). Some works were also carried
out using microneedles (MN) to enhance the transdermal delivery of insulin (8-12). While these works show the potential of using MN for enhancement of insulin delivery, and no works depicting a systematic approach to evaluate the overall dependence of insulin permeation on various parameters, for example, the MN lengths (MN density in a patch) and insulin donor concentration, etc. have been explored in detail.

In addressing this issue, we have carried out a series of well-defined in vitro experiments for the evaluation of insulin transdermal permeation using (i) insulin solutions of two different strengths and volumes as donor vehicle, (ii) the effect and relative efficacy of different lengths of MN on insulin permeation enhancement. Moreover, the obtained data was subjected to mathematical treatment using scaling analyses to obtain correlations between dimensionless amount of insulin permeated ($C_t/C_s$) and various variables of the study like surface area ($S_a/L^2$) and thickness ($h/L$) of skin based on the Buckingham $\pi$ theorem (13). Numerical simulations of the in vitro experiments using histological section images and passive diffusion coefficient values were also carried out in order to simulate the insulin permeation process under realistic conditions and gain insights into the phenomenon of insulin transport behaviour and insulin distribution in the MN treated skin (14). Commercially available MN arrays (AdminPatch®) with four different needle lengths (0.6, 0.9, 1.2 and 1.5 mm) and MN density were utilized for the purpose of this study. Also, a new RP-HPLC-PDA method was developed for the insulin analysis.

MATERIALS AND EXPERIMENTAL METHODS

Materials

The materials used for this research work include Insugen-R (Biocon, Bangalore, India), high performance liquid chromatography (HPLC) grade acetonitrile, water and formic acid (E. Merck, Mumbai, India), sodium chloride, isopropyl alcohol (S.D. Fine chem. Ltd, Mumbai,
India), and haematoxylin and eosin (Sigma-Aldrich, Dorset, UK). AdminPatch® arrays (0.6, 0.9, 1.2 and 1.5 mm MN lengths) were purchased from Admin Med (Sunnyvale, CA, USA). The pig ears were obtained from a local slaughter house.

Methods

Analytical method

The insulin analysis was performed on a Shimadzu chromatographic system equipped with HPLC Shimadzu pump LC-20AD, SIL-20A auto sampler with 200µL loop volume, programmable variable wavelength PDA detector SPD-M20A VP, and Inertsil C18 column (250×4.6 mm, 5 µm). The HPLC system was equipped with LC-solution software to acquire and process the data. The mobile phase consisted of 0.02% v/v formic acid and acetonitrile (40:60 v/v) and pumped at a flow rate of 1.0 mL/min. The eluents were monitored at a wavelength of 215 nm at ambient temperature with an injection volume of 20µL. An appropriate volume of the insulin stock solution was diluted with 0.9% w/v sodium chloride to get the required standard solutions at a concentration range of 5-40µg/mL. The proposed method was validated as per ICH guidelines (15).

Preparation of 0.9% (w/v) sodium chloride solution

0.9g of sodium chloride was accurately weighed and transferred to a clean and dry 100mL volumetric flask containing 50mL of HPLC water and dissolved. The volume was made up to mark to get 0.9% (w/v) sodium chloride solution.

Determination of insulin stability

The stability of insulin in saline solution was studied over a period of 48 h by storing 1mL aliquots of 30µg/mL insulin in centrifuge tubes at a temperature of 37°C. Samples were
withdrawn at different time intervals for 48 h and analysed for insulin content by RP-HPLC-PDA method.

**Skin preparation**

The ears were collected from the local abattoirs (pigs aged about 6-7 months) and the ears were transported to the laboratory in a cooling box without previous treatment. Freezing of the skin was avoided during transport. In the laboratory, the pig ears were washed carefully with water. The hair was removed from the external part of pig ear using an electrical hair clipper. Then, the full-thickness skin was separated from the external part of the pig ear using a scalpel and excess fat under the skin was removed to a thickness of 1.2 mm for all the skin samples. Dermis side was wiped with isopropyl alcohol to remove residual adhering fat. The pieces of skin obtained were individually wrapped in plastic bags and stored in a deep freezer at -20°C till further use.

**MN treatment of pig ear skin**

Prior to the permeation experiments, the frozen skin samples were brought to room temperature and then the skin pieces were carefully washed with saline solution in a petridish. The MN arrays differing in their needle lengths (0.6mm, 0.9mm, 1.2mm and 1.5mm) were pressed over the skin pieces at a constant thumb pressure. Photographs of the MN arrays with different needle lengths were shown in Fig. 1. The MNs were periodically checked in between usage for potential damages of the needle under a stereo microscope.

**Histological examination and calculation of penetration depth**

The histological sections of the skin samples without and with MN treatment were observed under the PZRM-700 microscope (Quasmo, Haryana, India). Skin samples were stained with hematoxylin and eosin (H&E) stains for visualization of skin layers and to display a clear
indentation of the MN penetration. The depth of MN penetration into skin was also calculated
with the help of ToupView 3.2 Software (AmScope, Irwin, USA).

**In vitro permeation studies**

Franz diffusion cell apparatus (Orchid Scientifes, Nasik, India) consisting of a water
circulation system, a water heater and an eight stage magnetic stirrer was used to carry out
permeation studies. The diffusion cells (1.77 cm² diffusional area and a receptor volume of
14mL) were employed for conducting the permeability studies and the donor compartment
was charged with insulin solutions (i.e., 40 and 100 IU/mL at 0.5 and 1mL donor volumes)
while the receiving compartment was loaded with saline solution.

Pig ear skin was mounted between donor and receptor compartments, with the stratum
corneum side facing towards the donor compartment and clamped. The receptor medium was
magnetically stirred at a speed of 600 rpm for uniform distribution of insulin. Care was taken
to prevent possible entrapment of air bubbles under the skin (dermis) and in receptor solution.
The surface of the skin was maintained at 32°C using a circulating water bath. After
equilibration, insulin solution was charged on to the skin. At predetermined time points, 0.5
mL samples were withdrawn from the receptor fluid and replaced with fresh medium
immediately. The amount of insulin in samples was analysed by RP-HPLC-PDA method.
The insulin skin permeation profiles were plotted for passive and MN (0.6, 0.9, 1.2 and 1.5
mm) treated skin permeation studies. The flux values and respective lag time values were
obtained from the slope and X-intercept of the steady state portion of the permeation profiles.

**Insulin content in skin**

Insulin retained within the skin was measured at the end of the experiment. The skin tissue
exposed to the donor solution was cut with a scalpel and rinsed with water and blotted with a
paper towel in order to remove the adhered insulin to the surface. The skin was then minced with a scalpel, and placed in a pre-weighed vial. The insulin was extracted from the skin by equilibrating with 1mL of acetonitrile at room temperature on an orbital shaker (60 rpm). Samples were analysed by HPLC to determine the insulin content.

**Scaling Analyses**

Scaling analyses were performed using amount of insulin permeated \( (C_t/C_s) \) and other variables of the study like surface area \( (S_a/L^2) \) and thickness \( (h/L) \) of skin using the Buckingham \( \pi \) theorem where it is defined that the dimensionless concentration of a drug, which permeates through skin sample, can be defined in terms of key non-dimensional parameters, e.g., MN lengths (13). Full details of the approach for the non-dimension analyses have been discussed earlier (13), and therefore they are not discussed in this paper.

Eq. 1 describes the relationship of all the parameters used for such analyses and the various method parameters used in this study for scaling analyses are given in Table I.

\[
\frac{C_t}{C_s} = K \left[ \frac{S_a L^4 K_e}{V_d h D} \right]^n \tag{1}
\]

Where, \( K \) is a dimensionless constant and \( n \) is an unknown power; \( C_t \) and \( C_s \) are the amount of drug permeated at a given time \( t \) (6 h) and the amount of drug loaded for diffusion (surface concentration on skin); \( S_a \) is the surface area of the patch or MN treated area of the skin; \( L \) is the length of MN; \( K_e \) is the first order elimination constant of drug; \( V_d \) is the volume of receptor fluids \( (in \ vitro) \); \( h \) is the thickness of skin and \( D \) is the diffusion coefficient of insulin in skin. Using Eq. 1, the correlations between the groups referring to the dimensionless insulin concentration \( (C_t/C_s) \) against different dimensionless parameters of study, \( h/L \) and \( S_a/L^2 \), have been established considering that all other variables remain unchanged.
Numerical Simulation of Permeation Experiments

Simulations were carried out using a MATLAB (Math Works, MA, USA) program, which was employed to prepare the microphotographs of histological sections of skin treated with MN. These images, coupled with the experimental parameters, e.g., passive diffusion coefficient obtained from the *in vitro* studies were imported into a simulator software, COMSOL Multiphysics (COMSOL Multiphysics Pvt. Ltd., Stockholm, Sweden), in order to simulate the insulin transport behaviour across skin and predict the permeation profiles of insulin as per the procedures reported by Han and Das (14).

Statistical analysis of the data

Statistical analysis of the data and different parameters obtained with skin permeation experiments were computed with a one-way ANOVA analysis (Fischer’s LSD post hoc test) using SYSTAT 13 software (Systat Software Inc., CA, USA). Results with *p*-value less than 0.05 were considered to be statistically significant variance.

RESULTS

Analytical method

In the present investigation, a rapid, efficient RP-HPLC-PDA method was developed for the quantitative estimation of insulin. The method was validated according to the ICH guidelines and it complies with all specifications (15). The validation data was given in Table II. Insulin eluted at 6.08 min, which showed a good linearity in the concentration range of 5-40 µg/mL with a correlation coefficient of 0.999. The percent recoveries ranged between 98 and 102 (RSD < 2).
Determination of insulin stability

Stability of insulin in 0.9% w/v saline solution, over a period of 48 h was studied and the data revealed that the % variation in insulin content at different time intervals was found to be less than 2%. The results of the stability studies showed good insulin stability over the entire experimental duration with no significant degradation.

Histological examination and calculation of penetration depth

Histological sections were prepared using haematoxylin and eosin stain and representative microscopic images were shown in Fig. 4 (A). The photographs clearly indicated the stratum corneum barrier disruption and the formation of microconduits across the skin layers. The representative penetration depth values for the MNs used were calculated using ToupView® software and were found to be approximately 363.25, 521.16 and 642.34 µm for 0.6, 1.2 and 1.5 mm MN lengths.

In vitro permeation studies

Passive in vitro permeation studies were carried out using 40 and 100 IU/mL strength insulin solutions at 0.5 and 1.0 mL donor volumes. The amount of insulin permeated through skin at different time intervals was determined by the RP-HPLC-PDA method. The cumulative amounts of insulin permeated through intact pig ear skin at the end of 6 h were found to be 329.66 ± 23.78 and 355.93 ± 21.17 µg/cm² respectively for 0.5mL and 444.19 ± 19.53 and 452.84 ±27.57µg/cm² respectively for 1mL of 40 and 100 IU/mL insulin solutions. On the other hand, the steady state flux values were found to be 71.66 ± 3.72 and 76.95 ± 3.86 μg/cm²/h for 0.5mL donor volume and 91.05 ± 6.66 and 92.12 ± 6.75 μg/cm²/h for 1mL donor volume respectively for 40 and 100 IU/mL strength insulin solutions. Hence, for further MN treated studies, 1 mL of 100 IU/mL strength insulin solution was used as donor
vehicle. The cumulative amount of insulin permeated after treatment with 0.6, 0.9, 1.2 and
1.5 mm MN were found to be 536.35 ± 37.66, 624.27 ± 39.16, 734.28 ± 45.27 and 789.20 ±
38.33 µg/cm² respectively and the respective flux values were 105.59 ± 6.23, 123.6 ± 2.22,
140.67 ± 4.67 and 146.44 ± 3.83 µg/cm²/h. The permeation parameters viz. lag times,
permeability coefficients, diffusion coefficients and insulin content in skin were given in
Table III and the comparative permeation profiles were shown in Fig. 2.

Scaling analyses

It is well known that many parameters of MN, skin and the drug have great influence on the
overall permeation enhancement achieved by this technique. Using scaling analyses, the
effect of MN length with respect to dimensionless skin thickness (h/L) and dimensionless
surface area of skin (S_a/L^2) on the dimensionless amount of insulin permeated (C_t/C_s) were
determined (Fig. 3 (A), (B) respectively). Eqs. 2 & 3 describe such relationships between the
considered dimensionless groups within the given range.

\[
\frac{C_t}{C_s} = 0.364 \left[\frac{h}{L}\right]^{-0.434} \quad \text{for} \quad 0.8 \leq \frac{h}{L} \leq 2.0 \quad ---2
\]

\[
\frac{C_t}{C_s} = 1.036 \left[\frac{S_a}{L^2}\right]^{-0.217} \quad \text{for} \quad 78.5 \leq \frac{S_a}{L^2} \leq 491.5 \quad ---3
\]

These correlations were determined for given thickness and surface area of skin while the
MN length varies (0.6, 0.9, 1.2 and 1.5 mm). The R^2 values for the dimensionless groups
(C_t/C_s vs h/L and C_t/C_s vs S_a/L^2) was found to be ≥0.99.

Numerical simulations of permeation experiments

Microphotographs of histological sections can provide an efficient way of predicting the
extent of skin disruption by different MN, which may be used to develop accurate
simulations of permeation process. The various stages in the treatment of histological images by MATLAB and COMSOL were shown in Fig. 4.

In order to confirm the validity of the developed simulations, the permeation profiles obtained from in vitro transdermal permeation experiments and that from simulation (for 0.6 mm MN treatment) were compared (Fig. 5). The similarity factor ($f_2$) for both the profiles was computed and was found to be 50.4.

**DISCUSSION**

A rapid, specific and precise RP-HPLC-PDA method was developed for the quantitative estimation of insulin and the method was validated according to ICH guidelines. The validation parameters like specificity, linearity, accuracy, limit of detection, limit of quantification, precision, robustness, system suitability and stability were all within the official compendial limits. The developed method was employed for the estimation of insulin in various samples throughout the experiment. Stability of insulin in saline solution was determined over a period of 48h at 37°C and showed no significant degradation of insulin till the end of experimental duration.

AdminPatch® arrays different lengths (0.6, 0.9, 1.2, 1.5 mm) were used to study their effect on enhancement of insulin skin permeation (Fig. 1). In order to gain insights into the microconduits formed by the MN application, histological sections (Fig. 4 A) were prepared and evaluated. The MN insertions and stratum corneum disruption were clearly evident from the histological sections. The MN arrays penetrated through the cells without merely indenting them. Overall, the depth of penetration as measured by ToupView® software was found to be approximately 40-50% of the needle length and increase in needle length increased the penetration depth as supported by the **microconduits formed by different**
lengths of MNs i.e., 1.2 and 1.5 mm as shown in Fig. 4 A and which may be due to the resistance shown by skin for MN insertion as a result of its viscoelastic nature (8, 17).

In concurrence with the reports published earlier that a large amount of insulin penetrates through the skin after the application of high concentrations of insulin at the donor site, the passive diffusion experiments we conducted resulted in a 1.5 fold increase in the cumulative amount of insulin permeated by increasing insulin strength from 40IU to 100IU and volume from 0.5mL to 1mL as donor vehicle \((p<0.05)\) (11, 12). This increase in the insulin permeation may be attributed to increased chemical potential of insulin in donor compartment. Based on the above results, 100 IU/mL strength insulin solution at 1 mL donor volume was used for further MN application studies, the data from which was used for comparing the relative efficacy of MN of different lengths on enhancement of insulin permeation and for developing non-dimensional scaling analysis and numerical simulations of the experiments so as to attain better understanding on the insulin transport behaviour after MN application.

The permeation parameters of insulin with passive and MN treated studies were compared (Table III). The results inferred in a 1.18, 1.38, 1.62 and 1.74 fold increase in the cumulative amount of insulin permeated at the end of 6 h for 0.6, 0.9, 1.2 and 1.5mm MN lengths respectively when compared to passive permeation results. Similarly a 1.15, 1.34, 1.53, 1.6 fold increase in flux values and 1.15, 1.23, 1.41, 1.9 fold decrease in lag times were observed.

1cm² circular MN arrays (0.6, 0.9, 1.2 and 1.5 mm) possess 187, 85, 41 and 31 needles with an effective length of 0.5, 0.8, 1.1 and 1.4 mm, respectively. The viable epidermis, which is a cellular, avascular tissue measuring 50-100 μm thickness, poses a significant barrier activity for transdermal delivery of drugs along with the stratum corneum and that the removal of full epidermis by calibrated microderm abrasion increased skin permeability of insulin by 11 folds (18). The ability of longer MNs (1.2 and 1.5 mm) to create microconduits across the
depth of epidermis without microderm abrasion might explain the increased permeability of insulin even with relatively less number of pores created in skin.

The concerns of pain and damage to small capillaries in dermis, after application of longer MNs (1.5mm length) can be over ruled by the previously published data, which states that MN application (480 to 1450 µm) was significantly less painful to human volunteers (5 to 40% pain scores) when compared to 26-gauge hypodermic needle (19). Moreover, it was reported in a previous study that the skin reverted to its normal physiological structure within 8 h specifically after application of 1.0 mm MN rollers, while the injury by hypodermic needle still persisted after 24 h in vivo using rat model (10). The depth of MN penetrated into the skin layers we observed was found to be 40-50 % of the MN length, further strengthens the above statements that nerve damage and pain on MN application are less probable.

In a previous study, MNs of 800 µm in length loaded with 0.13, 0.25 and 0.44 IU of bovine insulin, were fabricated from hyaluronic acid resulted in the release of insulin (>90%) within 1 h in both in vitro and in vivo (rat model) permeation studies and that the delivery rate from insulin loaded MNs was found to be comparable to that obtained with subcutaneous injection. Poke and solution application technique employed in our investigation using MN arrays of 1.2 and 1.5 mm length resulted in 37 and 40 % permeation of insulin loaded dose at the end of 6 h. Moreover, no saturation or plateau signs in the permeation profile were observed after MN application (Fig. 2). This can be extrapolated to a continuous and controlled insulin delivery via the skin under in vivo conditions for more than 6 h.

In corroboration with the data we obtained in this investigation, an in vivo study on rat model with a similar “poke and solution application” technique, using MN rollers (0.25, 0.5 and 1 mm), was reported by Liu et al., showing a positive relationship between the MN length and
hypoglycemic effect produced thereof (10). However, a superior hypoglycemic effect in vivo may be anticipated with MN arrays application, as the number of MNs piercing the skin per unit area is more on arrays than on rollers.

Insulin retained within the skin was measured at the end of the experiment in order to have an idea of insulin retained in skin layers after the permeation studies (Table III). Even though, there is no correlation of insulin skin content with different experiments, significant amounts of insulin was distributed in skin layers at the end of the experiments indicating potential skin deposition of insulin.

The scaling analyses were developed between various dimensionless parameters (Fig. 3 A, B) in order to generalise the effect of MN length (L), skin thickness (h) and surface area of skin (Sa) exposed on the overall amount of insulin permeated (Ct/Cs) (13). Good correlation ($R^2 \geq 0.99$) was observed between the dimensionless parameters and can be used to predict the amount of insulin permeated (Ct/Cs) with high accuracy for other MN lengths in the range of 0.6-1.5 mm.

Besides the scaling analyses, a set of well-defined numerical simulations of the permeation experiments were carried out in order to gain better insights into the effects of MN design, force of insertion of MN, thickness of skin, etc. in enhancing the insulin permeation, and also to obtain the information about insulin distribution within the skin during permeation, which are difficult to obtain directly from the experimental data. In order to carry out simulation studies of high accuracy, the relative ability of the MNs in creating microconduits in the skin should be understood precisely. It is well known now that owing to the viscoelastic nature of skin, the microconduits created do not have the same dimensions as the MN, but may vary significantly (8, 16), thereby limiting the applicability of MN design parameters to carry out such simulations. Microphotographs of histological sections can provide an efficient way of
predicting the extent of skin disruption by different MNs, which may be used to develop
accurate simulations of the drug(s) permeation process (14). The numerical simulations
carried out using MATLAB (Fig. 4 B, C) and COMSOL (Fig. 4 D) software, based on in
vitro passive diffusion coefficient values and histological section images (of corresponding
MN geometry) were able to provide information regarding drug distribution within skin at
any time point and depth (14).

The similarity factor ($f_2$) for the in vitro permeation profile and the simulated profile was
found to be 50.4, which indicates that the developed simulations for insulin permeation under
given conditions were in good agreement with the experimental results and therefore can be
used to accurately predict permeation profiles of insulin using histological skin sections
treated specific shape and size of MNs.

Furthermore, these simulation studies can also be used to predict the permeation profiles of
other drugs with different dimensions and designs of MNs using the respective histological
section images and the passive diffusion coefficient of the drug in skin. These scaling and
simulation studies would help researchers in optimising the MN geometry and other
experimental conditions in further improving the degree of enhancement of insulin or other
drugs.

CONCLUSION

Transdermal delivery of therapeutic agents like insulin can be of great clinical advantage, as
it is relatively less invasive, provides a continuous delivery with low frequency of
administration and thus increased patient compliance. Our study inferred in a significant
enhancement in insulin permeation across the pig era skin and is donor concentration and
volume dependent. The permeation of insulin after MN application increased with increase in
needle length. The developed scaling correlations and numerical simulations can be of great
research value for understanding and optimising insulin delivery through transdermal route. Thus, developing appropriate MN assisted transdermal insulin delivery systems may be a promising alternative for injectable insulin therapy. However, further *in vivo* studies are needed to be carried out to evaluate the therapeutic efficacy of this technique and its applicability to human use.

**ACKNOWLEDGEMENTS**

The authors are thankful to the Siddhartha Academy of General and Technical Education, Vijayawada, for providing facilities and support to carry out this research work and NRI Academy of Medical Sciences, Guntur, for providing the facilities required for the histological examination of the skin samples.

**CONFLICT OF INTEREST**

The authors report no conflicts of interest.
REFERENCES


9. Liu S, Jin MN, Quan YS, Kamiyana F, Katsumi H, Sakane T, Yamamoto A. The development and characteristic of novel microneedle arrays fabricated from


15. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Validation of text and methodology Q2 (R1), 2005.


### Table I: Model parameters for dimensional analyses of data.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration for medication (calculation): $t_m$ (h)</td>
<td>6</td>
</tr>
<tr>
<td>Surface area of skin exposed for permeation: $S_a$ (cm$^2$)</td>
<td>1.77</td>
</tr>
<tr>
<td>Thickness of stratum corneum: $h_{sc}$ (cm)</td>
<td>0.002</td>
</tr>
<tr>
<td>Total thickness of membrane (distance to blood vessel): $h$ (cm)</td>
<td>0.12</td>
</tr>
<tr>
<td>Effective skin thickness: $h_e$ (cm)</td>
<td>Variable</td>
</tr>
<tr>
<td>Diffusion coefficient in viable skin: $D_{vs}$ (cm$^2$/s)</td>
<td>Variable</td>
</tr>
<tr>
<td>Volume of receptor compartment (distribution): $V_d$ (ml)</td>
<td>14</td>
</tr>
<tr>
<td>Skin surface/Donor concentration: $C_s$ (mg/ml)</td>
<td>3.5</td>
</tr>
<tr>
<td>MN length: $L$ (cm)</td>
<td>Variable</td>
</tr>
</tbody>
</table>
**Table II: Linearity, precision and accuracy data of Insulin**

**Linearity (n=3)**

<table>
<thead>
<tr>
<th>Range</th>
<th>5-40 µg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regression equation</td>
<td>$y = 2307x - 20464$</td>
</tr>
<tr>
<td>Correlation coefficient</td>
<td>$R = 0.998$</td>
</tr>
<tr>
<td>Regression coefficient</td>
<td>$R^2 = 0.996$</td>
</tr>
</tbody>
</table>

**Precision (n=6)**

<table>
<thead>
<tr>
<th>Average peak area of the standard sample (%RSD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>663000 (1.9)</td>
</tr>
</tbody>
</table>

**Accuracy (n=3)**

<table>
<thead>
<tr>
<th>% Level of addition</th>
<th>Mean Percent Recovery (%RSD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>101.3 (0.351)</td>
</tr>
<tr>
<td>100</td>
<td>100.9 (0.433)</td>
</tr>
<tr>
<td>120</td>
<td>101.6 (1.028)</td>
</tr>
</tbody>
</table>
Table III: *In vitro* transdermal permeation parameters of insulin

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Passive</td>
</tr>
<tr>
<td>Lag time (h)</td>
<td>1.13 ± 0.11</td>
</tr>
<tr>
<td>Permeability Coefficient (cm/h) x10^{-3}</td>
<td>26.07 ± 1.62</td>
</tr>
<tr>
<td>Diffusion Coefficient (cm²/s) x10^{-7}</td>
<td>8.938 ± 0.55</td>
</tr>
<tr>
<td>Insulin content in skin (ng/g)</td>
<td>651.75 ± 120.94</td>
</tr>
</tbody>
</table>
Fig. 1

A

B

C

D
Fig. 2

Cumulative amount of Insulin permeated (µg/cm²) vs. Time (h)

- Passive
- 0.6 mm
- 0.9 mm
- 1.2 mm
- 1.5 mm
Fig. 3
<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Image] 0.6 mm MN</td>
<td>[Image] 1.2 mm MN</td>
<td>[Image] 1.5 mm MN</td>
</tr>
<tr>
<td>[Image]</td>
<td>[Image]</td>
<td>[Image]</td>
</tr>
</tbody>
</table>

**Fig. 4**
Fig. 5

0.6mm MNs experimental results
0.6mm MNs simulation results

Mean cumulative amount of insulin permeated (µg/cm²)

Time (hrs)

*f₁ ≥ 50
LEGENDS TO FIGURES

Fig. 1. Photographs of MN arrays - (A) 0.6 mm; (B) 0.9 mm; (C) 1.2 mm; (D) 1.5 mm

Fig. 2. Mean comparative *in vitro* skin permeation profiles of insulin

Fig. 3. Scaling relationships for permeation of insulin - (A) General correlation between dimensionless insulin concentration ($C_t/C_s$) and dimensionless skin thickness ($h/L$); (B) General correlation between dimensionless insulin concentration ($C_t/C_s$) and dimensionless surface area ($S_a/L^2$)

Fig. 4. (A) The histological section images of skin; (B&C) Images treated and processed with MATLAB program (D) Images simulated in COMSOL

Fig. 5. Comparative transdermal permeation profiles of insulin from experimental and simulation studies